Shernan Holtan, MD, University of Minnesota, Minneapolis, MN, comments on the potential of amphiregulin as a biomarker to monitor patients during treatment of acute graft-versus-host disease (GvHD). Using samples collected from two prospective clinical trials, it was found that amphiregulin levels decreased in patients responding to treatment. This biomarker could be useful in clinical practice to monitor patients and determine whether a patient’s symptoms are related to GvHD or not. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.

свернуть